We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-2.1%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.12B
AUM Growth
-$506M
Cap. Flow
-$1.33B
Cap. Flow %
-25.88%
Top 10 Hldgs %
36.5%
Holding
171
New
28
Increased
20
Reduced
18
Closed
38

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$561M
2
WGS icon
GeneDx Holdings
WGS
+$144M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$39.4M
4
GKOS icon
Glaukos
GKOS
+$34.3M
5
AERI
Aerie Pharmaceuticals
AERI
+$31.4M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$54.4M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$54.1M
3
QDEL icon
QuidelOrtho
QDEL
+$52.4M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$45.3M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$42.5M

Sector Composition

Rank Sector Weight
1 Healthcare 66.12%
2 Financials 1.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OM icon
51
Outset Medical
OM
$80.5M
$19.8M 0.39%
26,708
– –
BPMC
52
DELISTED
Blueprint Medicines
BPMC
$19.1M 0.37%
185,354
-96,400
-34% -$8.98M
PROF
53
Profound Medical
PROF
$266M
$19M 0.37%
1,297,797
– –
MAAC
54
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
$18.7M 0.37%
+2,000,000
New +$19.9M
CALC icon
55
CalciMedica
CALC
$11.1M
$17.5M 0.34%
377,265
– –
ERAS icon
56
Erasca
ERAS
$6.57B
$16.7M 0.33%
+786,660
New +$16.2M
CYPH
57
Cypherpunk Technologies Inc
CYPH
$66.8M
$16M 0.31%
+400,000
New +$7.52M
ORTX
58
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$16M 0.31%
694,942
– –
WVE icon
59
Wave Life Sciences
WVE
$1.15B
$15.8M 0.31%
3,214,340
-1,614,729
-33% -$9.79M
DALS
60
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$15.7M 0.31%
+1,600,000
New +$15.8M
JBIO
61
Jade Biosciences
JBIO
$1.23B
$15M 0.29%
20,408
– –
LENZ
62
LENZ Therapeutics
LENZ
$181M
$14.9M 0.29%
129,473
– –
BCAB icon
63
BioAtla
BCAB
$5.63M
$13.7M 0.27%
9,286
+4,378
+89% +$8.53M
COGT icon
64
Cogent Biosciences
COGT
$6.92B
$13.5M 0.26%
1,601,000
– –
SPRB
65
Spruce Biosciences
SPRB
$116M
$13.2M 0.26%
29,333
+2,040
+7% +$1.28M
QSI icon
66
Quantum-Si Incorporated
QSI
$171M
$11.7M 0.23%
1,400,000
– –
RXST icon
67
RxSight
RXST
$235M
$11.4M 0.22%
+900,000
New +$12.4M
TYRA icon
68
Tyra Biosciences
TYRA
$1.86B
$11M 0.21%
+625,000
New +$11.9M
ANNX icon
69
Annexon
ANNX
$850M
$10.9M 0.21%
583,913
– –
DH icon
70
Definitive Healthcare
DH
$71.4M
$10.7M 0.21%
+250,000
New +$11.1M
EUCRU
71
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$9.95M 0.19%
1,000,000
– –
TLSI icon
72
TriSalus Life Sciences
TLSI
$265M
$9.93M 0.19%
+999,999
New +$9.79M
SRSAU
73
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$9.88M 0.19%
1,000,000
– –
SNRH
74
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
$9.77M 0.19%
+1,000,000
New +$9.71M
REVH
75
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$9.71M 0.19%
+1,000,000
New +$9.74M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2021 Portfolio in Review

As of Q3 2021, Deerfield Management held 171 positions worth $5.12B, down 9% from $5.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Deerfield Management withdrew a net $1.33B in Q3 2021, closing 38 positions and reducing 18 holdings. Its most notable exit was Zimmer Biomet, an estimated $54.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 68% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Nuvalent worth $436M.

  • Deerfield Management's largest Q3 2021 buy was Nuvalent: 19,341,024 shares worth $436M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2021, an estimated $39.4M increase.
  • Deerfield Management's biggest Q3 2021 reduction was BioCryst Pharmaceuticals, cutting an estimated $41M.
  • Deerfield Management fully exited Zimmer Biomet in Q3 2021, selling an estimated $54.4M.
  • Deerfield Management's ten largest holdings make up 37% of its $5.12B portfolio in Q3 2021.
  • Deerfield Management opened 28 new positions and closed 38 in Q3 2021.
  • Deerfield Management's portfolio value fell 9% quarter-over-quarter to $5.12B.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.